Drug news
Shire sells Dermagraft assets to Organogenesis
Shire plc has announced that it has entered into a definitive agreement pursuant to which it has sold its Dermagraft assets to Organogenesis Inc. Dermagraft is a living skin substitute indicated for use in the treatment of full-thickness Diabetic Foot Ulcers and is approved for use in the US and Canada. Going forward Organogenesis will assume all financial and management responsibility for Dermagraft.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.